Trials / Unknown
UnknownNCT05410028
New Serum Biomarkers for Monitoring Early Diagnosis of Ovarian Cancer Recurrence
New Serum Biomarkers for Monitoring Early Diagnosis of Ovarian Cancer Recurrence Via Analysis of Immunoinflammation-related Protein Complexes in Blood
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,000 (estimated)
- Sponsor
- Peking Union Medical College Hospital · Academic / Other
- Sex
- Female
- Age
- 20 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
In this study, mass spectrometry was used to analyze immune inflammation-related protein complexes, post-translational modified glycopeptide omics and tumor-related metabolomics in serum, respectively, in order to find potential metabolic small molecule biomarkers or marker profiles that can be used for early diagnosis of cancer recurrence.
Detailed description
Time cohort study: patients with confirmed ovarian epithelial cancer at different time cutoff points before treatment, after surgery, during chemotherapy, and after chemotherapy, until clinically confirmed patients relapse. At least 50 patients are expected to be enrolled.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | No intervention in clinical treatment | No intervention in clinical treatment |
Timeline
- Start date
- 2022-03-03
- Primary completion
- 2024-03-03
- Completion
- 2026-03-03
- First posted
- 2022-06-08
- Last updated
- 2022-06-08
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05410028. Inclusion in this directory is not an endorsement.